New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 5, 2014
09:29 EDTRAREUltragenyx announces license agreement with UniQuest, new U.S. patent
Ultragenyx Pharmaceutical announced a license agreement with UniQuest Pty Limited for intellectual property related to the treatment of refractory epilepsy and other seizure-related and neurologic disorders with triheptanoin. The intellectual property originated from research on epilepsy and other neurologic models conducted at The University of Queensland. Separately, a United States patent has been issued with claims directed to compositions of triheptanoin above a certain level of purity. The patent term expires in October 2025. A second U.S. patent with claims directed to compositions of triheptanoin in a dosage unit was issued in August 2013 and expires in June 2020. These patent terms do not include any potential for patent term extension of up to five additional years. Similar claims are either granted or being pursued by Ultragenyx in other territories outside the U.S.
News For RARE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 1, 2015
10:05 EDTRAREOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: 8point3 Energy (CAFD) initiated with an Equal Weight at Barclays... AMAG Pharmaceuticals (AMAG) initiated with an Outperform at Raymond James... Acadia (ACHC) initiated with an Outperform at Leerink... Acorda Therapeutics (ACOR) initiated with a Market Perform at Raymond James... Alexion (ALXN) initiated with a Strong Buy at Raymond James... Amedisys (AMED) initiated with an Outperform at Wells Fargo... Amgen (AMGN) initiated with a Market Perform at Raymond James... Amplify Snack Brands (BETR) initiated with a Neutral at Credit Suisse... BioMarin (BMRN) initiated with an Outperform at Raymond James... Biogen (BIIB) initiated with a Strong Buy at Raymond James... Celgene (CELG) initiated with a Strong Buy at Raymond James... CoreLogic (CLGX) initiated with a Neutral at SunTrust... Digi International (DGII) initiated with an Overweight at Stephens... First Solar (FSLR) initiated with an Overweight at Barclays... LHC Group (LHCG) initiated with an Outperform at Wells Fargo... Lancaster Colony (LANC) initiated with a Buy at BB&T... McCormick (MKC) initiated with a Buy at BB&T... NephroGenex (NRX) initiated with a Buy at H.C. Wainwright... Omega Protein (OME) initiated with a Hold at BB&T... Preferred Apartment (APTS) initiated with an Outperform at FBR Capital... Qorvo (QRVO) initiated with an Outperform at CLSA... Regeneron (REGN) initiated with an Outperform at Raymond James... Skyworks (SWKS) initiated with an Outperform at CLSA... SunPower (SPWR) initiated with an Equal Weight at Barclays... TESARO (TSRO) initiated with a Strong Buy at Raymond James... Ultragenyx (RARE) initiated with an Outperform at Raymond James... VEREIT (VER) initiated with a Buy at Goldman... Westmoreland (WLB) initiated with an Outperform at BMO Capital.
09:08 EDTRAREUltragenyx presents data from LC-FAOD patients treated with triheptanoin
Ultragenyx Pharmaceutical announced the presentation of open-label data from five infants with cardiomyopathy due to long-chain fatty acid oxidation disorders, or LC-FAOD, treated with triheptanoin. Severely affected LC-FAOD patients can present early in life with severe cardiomyopathy, arrhythmia, heart failure, hypoglycemia, hepatic dysfunction, and rhabdomyolysis that can lead to death. The data were presented at the Society for the Study of Inborn Errors of Metabolism, or SSIEM, Annual Symposium in Lyon, France. Case reports from five infant patients with moderate or severe cardiomyopathy due to LC-FAOD were presented. All patients were detected by newborn screening and managed with standard treatment, including medium-chain triglyceride oil. While on the standard of care, the patients were hospitalized with heart failure that required cardiac support and, in some cases, resuscitation. The patients discontinued medium-chain triglyceride oil and then began to receive triheptanoin on an expanded access basis.
August 31, 2015
19:26 EDTRAREUltragenyx initiated with an Outperform at Raymond James
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use